One of the most compelling untold stories in medicine has been the dramatic reduction in mortality among heart failure patients over the past 30 years, and Penn State Health Milton S. Hershey Medical Center has been at the forefront of this effort.
Hershey Medical Center is certified by the United Network of Organ Sharing (UNOS) and has been offering heart transplant surgery since 1984. John Boehmer, MD, heart failure program director, says, “In the 1980s, heart failure was associated with an extraordinarily high mortality rate, and between the use of medical therapy, mechanical devices such as implantable defibrillators, pacemakers and left or right ventricular assist devices (LVADs, RVADs), as well as transplantation, that mortality has been reduced by nearly 80 percent. This improvement has come in incremental steps that have often gone unnoticed.” Continue reading
Cardiac electrophysiologists have been placing implantable cardioverter defibrillators (ICDs) for many years, with the standard system using a transvenous device. Although small, the device required physicians to implant directly into the heart and used leads with limited durability. Several years ago, subcutaneous implantable cardioverter defibrillators (S-ICDs) were introduced, but the first generation S-ICD was largely restricted to adult patients, due to its size and the lack of remote monitoring capability. A newer, smaller model of the device was released in summer 2015, allowing pediatric electrophysiologists at Penn State Children’s Hospital to implant this device in children.
EMBLEM TM S-ICD device.
This second-generation device is smaller and thinner, projected to last 40 percent longer than the previous version and is enabled for remote patient monitoring. It eliminates many of the potential complications associated with transvenous leads and has demonstrated excellent real-world results, including low complication rates and high conversion efficacy.1,2 “The smaller size and remote monitoring capability of the second-generation S-ICD have made it more compatible for our patient population, and we do not have to implant anything directly into the heart,” says Jason R. Imundo, MD, pediatric cardiologist and electrophysiologist, Penn State Children’s Heart Group. Instead, the device is implanted just under the skin near the ribs. Continue reading
The Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure has long been used to treat portal vein hypertension in patients with cirrhosis and other conditions, prior to liver transplant surgery, however, it could not be used in those with a complete portal vein occlusion. 1 The transsplenic approach allows interventional radiologists (IRs) to bypass the liver.1 Penn State Health Milton S. Hershey Medical Center is one of a few teaching hospitals in Pennsylvania to offer this innovative approach.
In the transsplenic approach, clinicians use a splenic sheath and lasso snare, transverse the spleen and continue the procedure using X-ray, achieving end-to-end anastomosis, which allows for balloon angioplasty in the blocked vein and facilitates completion of the TIPS. Portal veins are patent and anatomically normal nearly 80 percent of the time when imaged months later. Continue reading
As the population ages, the number of ICU beds and demand for intensivists is increasing, but these specially-trained physicians are in dramatically short supply.1 Over the last decade, the 30-bed Heart and Vascular Critical Care Unit (CCU) at Penn State Health Milton S. Hershey Medical Center has addressed this challenge with intensivist-led care teams that increasingly rely on nurse practitioners (NPs), while continuing to meet the complex needs of critically ill patients. Research suggests the model may confer a slight boost in ICU survival rates.2
The Heart and Vascular Institute plans to add one intensivist and five NPs to its current team of three intensivists and 11 NPs, according to Christoph Brehm, MD, and Angela Manoskey, CRNP. Continue reading
Two-thirds of primary liver cancer patients and 90 percent of secondary liver cancer patients have inoperable tumors that are unresponsive to systemic chemotherapy and may benefit from transarterial chemoembolization or radioembolization with yttrium-90 (Y-90), both minimally-invasive, palliative procedures. Although research shows transarterial chemoembolization and Y-90 are usually equivalent treatments for most intermediate-stage hepatocellular carcinomas (HCCs)1, Heart and Vascular Institute considers tumor blood supply when deciding which therapy would be most beneficial for a specific patient.
Image on the left: Pre-chemoembolization axial, contrast-enhanced CT scan at the level of the liver. White arrow shows a hypervascular lesion (33.8 mm x 31.6 mm) in segment 7 of the liver consistent with hepatocellular carcinoma.
Image on the right: Post-chemoembolization axial, contrast-enhanced CT scan at the same level as the previous image. White arrows show the treated lesion (22.4 mm x 24.0 mm) in segment 7. The lesion is no longer enhancing and has decreased in size.
By the year 2050, it is estimated that nearly 16 million people could suffer from atrial fibrillation (AF), but not all will tolerate long-term anticoagulant therapy.1 The WATCHMAN™ Left Atrial Appendage Closure (LAAC) device, the latest minimally invasive option at the Heart and Vascular Institute, can help bridge this clinical gap. In March, Penn State Health Milton S. Hershey Medical Center became the first in the region to implant the WATCHMAN device in non-valvular AF patients at increased risk for stroke and systemic embolism seeking an alternative to long-term warfarin therapy.
WATCHMAN™ is delivered via a transfemoral approach and is designed to close the left atrial appendage (LAA) to prevent migration of blood clots, thus reducing the risk of stroke and systemic embolism. Images provided courtesy of Boston Scientific.© 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
Penn State Health Milton S. Hershey Medical Center has joined two multicenter trials that evaluate a total artificial heart (TAH) and may save the lives of even more patients with irreversible biventricular heart failure (BVHF). The focus of the observational studies is the SynCardia® TAH, which was first approved by the FDA as a bridge to transplant in a 70cc size, based on a study of 81 patients, 79 percent of whom survived to receive a transplant.1
The first study examines the safety of the 70cc device for use as destination therapy in patients with life-threatening BVHF who are ineligible for cardiac transplant. To date, 12 centers, including Milton S. Hershey Medical Center, are set to enroll patients and follow them for six months to confirm the device’s benefits. Researchers define success as survival to six months without permanent deficits from stroke. Patients may also participate in a secondary arm of the trial to determine whether a broader patient population would also benefit from the device.2 Continue reading